Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Block listing Interim Review

18 Feb 2019 07:00

RNS Number : 2001Q
Realm Therapeutics PLC
18 February 2019
 

Realm Therapeutics plc

Block Listing Interim Review

 

Pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies Realm Therapeutics plc makes the following update on its block listing:

 

Date: 18 February 2019

 

Name of applicant:

Realm Therapeutics plc

Name of scheme:

Executive Omnibus Incentive Plan

Warrants

Figures for all schemes relate to ordinary shares

of 10 pence each

Period of return:

From: 18 August 2018 To: 15 February 2019

Balance of unallotted securities under scheme(s) from previous return:

2,055,362

21,257,021

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Nil

Less: Number of securities issued/allotted under scheme(s) during period:

Nil

Nil

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

2,055,362

21,257,021

 

 

Number and class of securities originally admitted:

 

* these securities have been adjusted for a 1 for 10 share consolidation which took effect on 2 July 2010

*20,000 and

*378,423 + *32,000 and 200,000

*196,087 and

*21,108

Dates of Admission:

 

7 August 2006 and 31 August 2007 and 15 August 2012

7 August 2006 and

31 August 2007

Name of contact:

Marella Thorell, Company Secretary

Telephone number of contact:

+1 484-321-2749

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRGIGDDSXBBGCU

Related Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Back to RNS